Reading RXST? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RXST free→Reading RXST? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RXST free→QuarterlyIQ Insights · RXST
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 6, 2026, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 12, 2026, RxSight, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial Report”) with the Securities and Exchange Commission to report, among other things, the appointment of Mark Wilterding as the Company’s Chief Financial Officer. The Company is filing this Current Report on Form 8-K/A to amend the Initial Report (i) t…
Results of Operations and Financial Condition. On February 25, 2026, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three and twelve months ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 13, 2025, the Company appointed Mark Wilterding as its Chief Financial Officer (and principal financial and accounting officer), effective January 11, 2026 (the “Effective Date”), replacing Shelley Thunen in such capacities. Prior to joining the Company, Mr. Wilterding, age 48, served as the senior vice president, global finance for Edw…
Results of Operations and Financial Condition. On January 11, 2026, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited fourth quarter and full-year 2025 financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under
of this Current Report on Form 8-K, does not affect the Company’s outlook or expectations for full-year 2025, and the Company continues to execute against its strategic and operational priorities. This report contains forward-looking statements, including statements concerning Company’s outlook or expectations for full-year 2025 and statements relating to the Company’s expectations and outlook as it continues to execute on its strategic and operational priorities. Such statements relate to fu…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 16, 2025, Shelley Thunen notified RxSight, Inc. (the “Company”) of her intention to transition from her position as the Company’s Chief Financial Officer (and principal financial and accounting officer), effective upon the sooner of the appointment of her successor as Chief Financial Officer or January 31, 2026. Ms. Thunen has agreed to…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 18, 2025, the Board of Directors (the “Board”) of RxSight, Inc. (the “Company”) appointed Eric Weinberg to the executive officer position of Chief Business Development Officer concurrent with his transition from the Chief Commercial Officer position on the same date. Also on December 18, 2025, the Board appointed Scott Gaines to serve a…
Results of Operations and Financial Condition. On November 5, 2025, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three and nine months ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. This Amendment No. 1 to Current Report on Form 8-K/A (the “Amendment”) amends the Current Report on Form 8-K of RxSight, Inc. (the “Company”) dated July 31, 2025 and filed with the Securities and Exchange Commission on August 4, 2025 (the “Original Form 8-K”), which disclosed the appointment of Raymond W. Cohen to the Board of Directors of the Comp…
Results of Operations and Financial Condition. On August 7, 2025, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three and six months ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 31, 2025, the board of directors (the “Board”) of RxSight, Inc. (the “Company”) increased the number of its authorized directors from nine to ten, and appointed Raymond W. Cohen to fill the newly created opening on the Board, effective July 31, 2025. Mr. Cohen was appointed as a Class I director for a term which will expire at the Company’s…
Results of Operations and Financial Condition. On July 8, 2025, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited second quarter financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under
Results of Operations and Financial Condition. On May 7, 2025, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under
Results of Operations and Financial Condition. On April 2, 2025, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited first quarter financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under
Results of Operations and Financial Condition. On February 25, 2025, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three and twelve months ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under
Importance-ranked changes since the prior daily snapshot.
Confidence changed from 'medium' to 'high'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.